Correlation Between Eupraxia Pharmaceuticals and Invizyne Technologies

Can any of the company-specific risk be diversified away by investing in both Eupraxia Pharmaceuticals and Invizyne Technologies at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Eupraxia Pharmaceuticals and Invizyne Technologies into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Eupraxia Pharmaceuticals Common and Invizyne Technologies Common, you can compare the effects of market volatilities on Eupraxia Pharmaceuticals and Invizyne Technologies and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Eupraxia Pharmaceuticals with a short position of Invizyne Technologies. Check out your portfolio center. Please also check ongoing floating volatility patterns of Eupraxia Pharmaceuticals and Invizyne Technologies.

Diversification Opportunities for Eupraxia Pharmaceuticals and Invizyne Technologies

-0.37

Correlation Coefficient

Eupraxia Pharmaceuticals  Invizyne Technologies

Very good diversification

The 3 months correlation between Eupraxia and Invizyne is -0.37. Overlapping area represents the amount of risk that can be diversified away by holding Eupraxia Pharmaceuticals Commo and Invizyne Technologies Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Invizyne Technologies and Eupraxia Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Eupraxia Pharmaceuticals Common are associated (or correlated) with Invizyne Technologies. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Invizyne Technologies has no effect on the direction of Eupraxia Pharmaceuticals i.e., Eupraxia Pharmaceuticals and Invizyne Technologies go up and down completely randomly.

Pair Corralation between Eupraxia Pharmaceuticals and Invizyne Technologies

Given the investment horizon of 90 days Eupraxia Pharmaceuticals is expected to generate 4.89 times less return on investment than Invizyne Technologies. But when comparing it to its historical volatility, Eupraxia Pharmaceuticals Common is 1.58 times less risky than Invizyne Technologies. It trades about 0.11 of its potential returns per unit of risk. Invizyne Technologies Common is currently generating about 0.35 of returns per unit of risk over similar time horizon. If you would invest  865.00  in Invizyne Technologies Common on September 15, 2024 and sell it today you would earn a total of  652.00  from holding Invizyne Technologies Common or generate 75.38% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	34.38%
Values	Daily Returns

Eupraxia Pharmaceuticals Commo  vs.  Invizyne Technologies Common

Eupraxia Pharmaceuticals

Risk-Adjusted Performance

8 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Eupraxia Pharmaceuticals Common are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Eupraxia Pharmaceuticals showed solid returns over the last few months and may actually be approaching a breakup point.

Invizyne Technologies

Risk-Adjusted Performance

27 of 100

Strong

Compared to the overall equity markets, risk-adjusted returns on investments in Invizyne Technologies Common are ranked lower than 27 (%) of all global equities and portfolios over the last 90 days. In spite of rather unfluctuating basic indicators, Invizyne Technologies exhibited solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Eupraxia Pharmaceuticals and Invizyne Technologies

The main advantage of trading using opposite Eupraxia Pharmaceuticals and Invizyne Technologies positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Eupraxia Pharmaceuticals position performs unexpectedly, Invizyne Technologies can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Invizyne Technologies will offset losses from the drop in Invizyne Technologies' long position.

The idea behind Eupraxia Pharmaceuticals Common and Invizyne Technologies Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.